Similar to the whole cohort, patients who received CBM588 exhibited significantly longer OS in the tumor PD-L1 < 1% (HR 0.20, 95% CI 0.05–0.72; log-rank test, p = 0.007, mOS not reached vs. 11 months, right panel) and PD-L1 1–49% (HR 0.36, 95% CI 0.13–0.98; log-rank test, p = 0.038, mOS not reached vs. 16 months, middle panel) cohorts. This evidence concerns the gene CD274 and neoplasm.